Paul Harmatz, MD, on Assessing D2S6 in Trials for MPS Type 2

Video

The pediatric gastroenterologist and professor in residence at University of California at San Francisco discussed biomarker findings from the phase 1/2 CAMPSIITE trial.

“Neurocognitive testing is looking quite promising, especially in children that are less than minus 2 standard deviations from normal level. The younger we’re able to treat patients when they are still functioning above the minus 2 standard deviation, it looks like we can get new skill attainment and positive benefits. When you're below that level, the hope is that we'll stabilize the disease, we may see some improvement, but not see worsening of the disease status.”

Image-guided injection of RGX-121 gene therapy (REGENXBIO) to the cisterna magna yielded dose-dependent reductions in cerebrospinal fluid glycosaminoglycans including D2S6 in participants with neuronopathic mucopolysaccharidosis type 2 (MPS2) treated in the phase 1/2 CAMPSIITE trial (NCT03566043).A phase 3 study is now enrolling.

Updated data from CAMPSIITE were presented by Paul Harmatz, MD, pediatric gastroenterologist and professor in residence, University of California at San Francisco, at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, held May 16-20, in Los Angeles, California. CGTLive spoke with Harmatz to learn more about the findings in the trial, including results from biomarker analyses. He discussed positive findings with neurocognitive testing and D2S6 in treated patients. He explained the importance of the D2S6 marker and why it can be more valuable to look at than heparin sulfate. He shared his belief that D2S6 is the most valuable marker to look at in trials assessing therapies for treating MPS2.

REFERENCE
Harmatz P, Ficicioglu C, Giugliani R, et al. RGX-121 gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in human study. Presented at: ASGCT 2023 Annual Meeting; May 16-20; Los Angeles, California. Poster #807
Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.